Tweet
Mol Pharm
. 2024 Jun 26.
doi: 10.1021/acs.molpharmaceut.4c00165. Online ahead of print. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants
Lei He 1 2 , Qian Wu 3 , Zhaoyong Zhang 4 , Lingling Chen 1 2 , Kuai Yu 4 , Leibin Li 1 2 , Qiong Jia 5 , Yanqun Wang 4 , Jianqiang Ni 2 , Chuanbin Wang 2 , Qi Li 2 , Xinyan Zhai 2 , Jincun Zhao 4 , Yuliang Liu 2 , Ruiwen Fan 5 , Yi-Ping Li 3
Affiliations
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evaded the efficacy of previously developed antibodies and vaccines, thus remaining a significant global public health threat. Therefore, it is imperative to develop additional antibodies that are capable of neutralizing emerging variants. Nanobodies, as the smallest functional single-domain antibodies, exhibit enhanced stability and penetration ability, enabling them to recognize numerous concealed epitopes that are inaccessible to conventional antibodies. Herein, we constructed an immune library based on the immunization of alpaca with the S1 subunit of the SARS-CoV-2 spike protein, from which two nanobodies, Nb1 and Nb2, were selected using phage display technology for further characterization. Both nanobodies, with the binding residues residing within the receptor-binding domain (RBD) region of the spike, exhibited high affinity toward the S1 subunit. Moreover, they displayed cross-neutralizing activity against both wild-type SARS-CoV-2 and 10 ο variants, including BA.1, BA.2, BA.3, BA.5, BA.2.75, BF.7, BQ.1, EG.5.1, XBB.1.5, and JN.1. Molecular modeling and dynamics simulations predicted that both nanobodies interacted with the viral RBD through their complementarity determining region 1 (CDR1) and CDR2. These two nanobodies are novel tools for the development of therapeutic and diagnostic countermeasures targeting SARS-CoV-2 variants and potentially emerging coronaviruses.
Keywords: SARS-CoV-2; cross-neutralization; nanobody; receptor-binding domain (RBD).
. 2024 Jun 26.
doi: 10.1021/acs.molpharmaceut.4c00165. Online ahead of print. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants
Lei He 1 2 , Qian Wu 3 , Zhaoyong Zhang 4 , Lingling Chen 1 2 , Kuai Yu 4 , Leibin Li 1 2 , Qiong Jia 5 , Yanqun Wang 4 , Jianqiang Ni 2 , Chuanbin Wang 2 , Qi Li 2 , Xinyan Zhai 2 , Jincun Zhao 4 , Yuliang Liu 2 , Ruiwen Fan 5 , Yi-Ping Li 3
Affiliations
- PMID: 38920116
- DOI: 10.1021/acs.molpharmaceut.4c00165
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evaded the efficacy of previously developed antibodies and vaccines, thus remaining a significant global public health threat. Therefore, it is imperative to develop additional antibodies that are capable of neutralizing emerging variants. Nanobodies, as the smallest functional single-domain antibodies, exhibit enhanced stability and penetration ability, enabling them to recognize numerous concealed epitopes that are inaccessible to conventional antibodies. Herein, we constructed an immune library based on the immunization of alpaca with the S1 subunit of the SARS-CoV-2 spike protein, from which two nanobodies, Nb1 and Nb2, were selected using phage display technology for further characterization. Both nanobodies, with the binding residues residing within the receptor-binding domain (RBD) region of the spike, exhibited high affinity toward the S1 subunit. Moreover, they displayed cross-neutralizing activity against both wild-type SARS-CoV-2 and 10 ο variants, including BA.1, BA.2, BA.3, BA.5, BA.2.75, BF.7, BQ.1, EG.5.1, XBB.1.5, and JN.1. Molecular modeling and dynamics simulations predicted that both nanobodies interacted with the viral RBD through their complementarity determining region 1 (CDR1) and CDR2. These two nanobodies are novel tools for the development of therapeutic and diagnostic countermeasures targeting SARS-CoV-2 variants and potentially emerging coronaviruses.
Keywords: SARS-CoV-2; cross-neutralization; nanobody; receptor-binding domain (RBD).